307 related articles for article (PubMed ID: 32370663)
1. Radioiodine-Induced Salivary Gland Damage Detected by Ultrasonography in Patients Treated for Papillary Thyroid Cancer: Radioactive Iodine Activity and Risk.
Horvath E; Skoknic V; Majlis S; Tala H; Silva C; Castillo E; Whittle C; Niedmann JP; González P
Thyroid; 2020 Nov; 30(11):1646-1655. PubMed ID: 32370663
[No Abstract] [Full Text] [Related]
2. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
[TBL] [Abstract][Full Text] [Related]
3. Ultrasonographic Features of Salivary Glands after Radioiodine Therapy in Patients with Thyroid Cancer.
Tsur N; Avishai G; Alkan U; Hod R; Shpitzer T; Bitton E; Gilat H
Laryngoscope; 2023 May; 133(5):1271-1275. PubMed ID: 36354236
[TBL] [Abstract][Full Text] [Related]
4. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Parotid and Submandibular Glands With Shear Wave Elastography Following Radioactive Iodine Therapy for Papillary Thyroid Carcinoma.
Rahatli FK; Turnaoglu H; Iyidir OT; Kirnap NG; Haberal KM; Aydın E; Uslu N
J Ultrasound Med; 2019 Feb; 38(2):357-362. PubMed ID: 30027680
[TBL] [Abstract][Full Text] [Related]
6. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment.
Caglar M; Tuncel M; Alpar R
Clin Nucl Med; 2002 Nov; 27(11):767-71. PubMed ID: 12394122
[TBL] [Abstract][Full Text] [Related]
7. The effect of selenium supplementation on sonographic findings of salivary glands in papillary thyroid cancer (PTC) patients treated with radioactive iodine: study protocol for a double-blind, randomized, placebo-controlled clinical trial.
Amini S; Golshani M; Moslehi M; Hajiahmadi S; Askari G; Iraj B; Bagherniya M
Trials; 2023 Aug; 24(1):501. PubMed ID: 37550760
[TBL] [Abstract][Full Text] [Related]
8. [Salivary gland damage after 131I therapy in patients with differentiated thyroid cancer. Preliminary report].
Macioszek A; Baczyk M; Kopeć T; Sowiński J
Endokrynol Pol; 2008; 59(5):403-10. PubMed ID: 18979451
[TBL] [Abstract][Full Text] [Related]
9. Salivary gland function in thyroid cancer patients with radioiodine administration history.
Krcalova E; Horacek J; Gabalec F; Zak P; Dolezal J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Sep; 164(3):277-283. PubMed ID: 31223135
[TBL] [Abstract][Full Text] [Related]
10. Computed tomography features of the major salivary glands after radioactive iodine ablation in patients with papillary thyroid carcinoma.
Kim DW
Radiol Med; 2018 Jan; 123(1):20-27. PubMed ID: 28932970
[TBL] [Abstract][Full Text] [Related]
11. Effects of Salivary Secretion Stimulation on the Treatment of Chronic Radioactive Iodine-Induced Sialadenitis.
Choi JS; Hong SB; Hyun IY; Lim JY; Kim YM
Thyroid; 2015 Jul; 25(7):839-45. PubMed ID: 25809840
[TBL] [Abstract][Full Text] [Related]
12. Salivary glands ultrasound examination after radioiodine-131 treatment for differentiated thyroid cancer.
Brozzi F; Rago T; Bencivelli W; Bianchi F; Santini P; Vitti P; Pinchera A; Ceccarelli C
J Endocrinol Invest; 2013 Mar; 36(3):153-6. PubMed ID: 22522602
[TBL] [Abstract][Full Text] [Related]
13. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
[TBL] [Abstract][Full Text] [Related]
14. Association of Xerostomia and Ultrasonographic Features of the Major Salivary Glands After Radioactive Iodine Ablation for Papillary Thyroid Carcinoma.
Soo Roh S; Wook Kim D; Jin Baek H
AJR Am J Roentgenol; 2016 Nov; 207(5):1077-1081. PubMed ID: 27504709
[TBL] [Abstract][Full Text] [Related]
15. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
[TBL] [Abstract][Full Text] [Related]
16. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
[TBL] [Abstract][Full Text] [Related]
17. Sialadenitis after radioiodine therapy. Analysis of factors that influence the response to medical treatment.
Geres AE; Mereshian PS; Fernández S; Rey Caro DG; Castro R; Podio R; Ojeda S
Endocrinol Nutr; 2015 Dec; 62(10):493-8. PubMed ID: 26459118
[TBL] [Abstract][Full Text] [Related]
18. Salivary morbidity and quality of life following radioactive iodine for well-differentiated thyroid cancer.
Dingle IF; Mishoe AE; Nguyen SA; Overton LJ; Gillespie MB
Otolaryngol Head Neck Surg; 2013 May; 148(5):746-52. PubMed ID: 23462656
[TBL] [Abstract][Full Text] [Related]
19. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L
Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy.
Jin M; Ahn J; Lee YM; Sung TY; Kim WG; Kim TY; Ryu JS; Kim WB; Shong YK; Jeon MJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):602-609. PubMed ID: 32981302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
